Abbott Laboratories (ABT) Total Liabilities (2009 - 2026)

Abbott Laboratories has disclosed Total Liabilities across 18 years of filings, most recently posting $57.7 billion for Q1 2026.

• Total Liabilities for Q1 2026 came in at $57.7 billion, down 29.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $57.7 billion (down 29.62% YoY), and the FY2025 annual result was $34.6 billion, down 38.53% from the prior year.
• Total Liabilities came in at $57.7 billion for Q1 2026 at Abbott Laboratories, up from $34.6 billion in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $82.9 billion in Q2 2022 to a low of -$32.4 billion in Q4 2022.
• The 5-year median for Total Liabilities is $56.3 billion (2024), against an average of $54.4 billion.
• Across the five-year window, Total Liabilities sank 88.12% in 2022 and surged 249.33% in 2023, its largest moves.
• Abbott Laboratories' Total Liabilities stood at -$32.4 billion in 2022, then soared by 249.33% to $48.3 billion in 2023, then increased by 16.37% to $56.3 billion in 2024, then plunged by 38.53% to $34.6 billion in 2025, then jumped by 66.93% to $57.7 billion in 2026.
• The last three Total Liabilities figures came in at $57.7 billion (Q1 2026), $34.6 billion (Q4 2025), and $33.2 billion (Q3 2025), per Business Quant data.